Cindy Boer

144 | Chapter 3.2 as yet no treatment options for preventing OA onset or progression, vitamin K may rep- resent a modifiable risk factor. These data provide strong rationale for a properly pow- ered randomized clinical trial of vitamin K in an appropriate patient population, such as those with insufficient vitamin K levels and/or MGP risk allele carriers. Additionally, these data lend support to the consideration of DOAC/NOACs in favour of VKAs when appropriate for a supported indication, and highlight the future possibility of genetic screening to identify individuals at high risk of OA incidence and progression. Data Availability Statement All relevant data supporting the key findings of this study are available within the ar- ticle and its supplementary data. Due to ethical and legal restrictions, individual-level data of the Rotterdam Study (RS) cannot be made publicly available. Data are available upon request to the data manager of the Rotterdam Study Frank van Rooij (f.vanrooij@ erasmusmc.nl) and subject to local rules and regulations. This includes submitting a proposal to the management team of RS, where upon approval, analysis needs to be done on a local server with protected access, complying with GDPR regulations Acknowledgments The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists. The generation and man- agement of GWAS genotype data for the Rotterdam Study (RS-I, RS-II, RS-III) was exe- cuted by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters, MSc, and Carolina Medina-Gomez, MSc, for their help in creating the GWAS database, and Linda Broer PhD, for the creation of the imputed data. Funding This research was funded by the Dutch Arthritis Foundation (ReumaNederland), (proj- ect nr DAA: 16-1-404). The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The Rotterdam